EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein






Vaccine 12(14): 1265-1269

Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein

Varicella-zoster virus (VZV)-seropositive human sera were shown to be reactive with the truncated VZV gpI(gE) candidate subunit vaccine (TgpI-511). To identify the location of antibody-binding sites (epitopes) on TgpI-511, three truncated forms of TgpI-511 glycoprotein (TgpI-124, TgpI-160, TgpI-316) DNA encoding the N-terminal region of this glycoprotein with amino acid residues of 124, 160 and 360, respectively, were inserted into the vaccinia virus genome. Infection of cells with recombinant vaccinia viruses resulted in the secretion of all three truncated gpI(gE) as well as TgpI-511 from the infected cells. Immunoprecipitation of these truncated glycoproteins with VZV-seropositive human sera and gpI(gE)-specific monoclonal antibodies identified the location of four new antibody-binding sites on the VZV TgpI-511 glycoprotein. In addition, tunicamycin treatment and O-glycanase digestion revealed the presence of both N-linked and O-linked oligosaccharides on TgpI-511. These results revealed the location of new epitopes on VZV TgpI-511 and demonstrated that the epitopes on TgpI-511 were recognized by human sera from VZV-seropositive individuals.

Accession: 009770392

PMID: 7531921

DOI: 10.1016/s0264-410x(94)80030-4

Download PDF Full Text: Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein



Related references

Vafai, A., 1994: Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein. Varicella-zoster virus (VZV)-seropositive human sera were shown to be reactive with the truncated VZV gpI(gE) candidate subunit vaccine (TgpI-511). To identify the location of antibody-binding sites (epitopes) on TgpI-511, three truncated forms of...

Hasan, U.A.; Murphy, B.J.; A.L.m, U.A.; Nye, K.; Wren, B.W.; Morrow, W.J.W., 1999: In vivo expression of a DNA vaccine encoding truncated and full length forms of Varicella-Zoster Virus glycoprotein E fused to enhanced green fluorescent protein. Immunology 98(suppl 1): 129, Dec

Kitamura K.; Namazue J.; Campo Vera H.; Ogino T.; Yamanishi K., 1986: Induction of neutralizing antibody against varicella zoster virus by varicella zoster virus by gp 3 and cross reactivity between varicella zoster virus gp 3 and herpes simplex viruses gb. Glycoprotein gp3 (64K) is one of the major proteins specified by varicella-zoster virus (VZV). This glycoprotein was purified on an immunoadsorbent consisting of monoclonal antibody (clone 8) against gp3 linked to protein A-Sepharose. Rabbits were...

Hasan, U.A.; Harper, D.R.; Wren, B.W.; Morrow, W.J.W., 2002: Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. The gE glycoprotein of varicella zoster virus (VZV) is involved with cell entry and it is the most abundant glycoprotein produced in VZV-infected cells. It is also the first glycoprotein to be recognized by the immune system and induces neutralizi...

Hasan, U.A.; Harper, D.R.; Wren, B.W.; Morrow, W.J.W., 2002: Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. The gE glycoprotein of varicella zoster virus (VZV) is involved with cell entry and it is the most abundant glycoprotein produced in VZV-infected cells. It is also the first glycoprotein to be recognized by the immune system and induces neutralizi...

Lee J.; Huang Z.; Vafai A.; Hayward A., 1991: Construction of a truncated varicella zoster glycoprotein iv gene in a vaccinia virus expression vector. Clinical Research 39(1): 59A

Hasan, U.A.; Harper, D.R.; A.L.m, U.A.; Murphy, B.J.; Nye, K.; Zheng, R.; Wren, B.W.; Morrow, W.J.W., 1999: Immunization with a DNA vaccine expressing a truncated form of Varicella-zoster virus glycoprotein E produced by inverse PCR mutagenesis. Immunology 98(suppl 1): 129, Dec

Montalvo E.A.; Grose C., 1986: Neutralization epitope of varicella zoster virus on native viral glycoprotein gp 118 varicella zoster virus glycoprotein gp iii. Varicella-zoster virus (VZV) specifies the formation of several glycoproteins, including a 118,000-Da mature structural product (gp118). The biologic and biochemical properties of gp118 were studied after production of murine monoclonal antibodies...

Ito, M.; Mizutani, K.; Kamiya, T.; Ihara, T.; Kamiya, H.; Sakurai, M.; Sugano, T.; Matumoto, Y., 1993: Inhibition of varicella-zoster virus (VZV) glycoprotein expression by a human monoclonal antibody against VZV glycoprotein III. Effects of human monoclonal antibodies (MAbs) against varicella-zoster virus (VZV) glycoproteins (gp) on VZV glycoprotein expression were analyzed by flow cytometry. Human embryonic fibroblast (HEF) cells were inoculated with cell-free VZV and cul...

Keller P.M.; Lonergan K.; Neff B.J.; Morton D.A.; Ellis R.W., 1986: Purification of individual varicella zoster virus glycoproteins gp i gp ii and gp iii and their use in elisa for detection of varicella zoster virus glycoprotein specific antibodies. We have utilized monoclonal antibodies in immune affinity chromatography to purify each of the 3 major glycoproteins of varicella-zoster virus (VZV), gpI, gpII, and gpIII, in immunologically active form. Upon injection into guinea pigs, each prepa...